While Spyre Therapeutics Inc has overperformed by 11.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SYRE fell by -9.79%, with highs and lows ranging from $40.26 to $10.91, whereas the simple moving average jumped by 20.63% in the last 200 days.
On September 26, 2025, Deutsche Bank started tracking Spyre Therapeutics Inc (NASDAQ: SYRE) recommending Buy. A report published by Leerink Partners on April 08, 2025, Initiated its previous ‘Outperform’ rating for SYRE. Wolfe Research also rated SYRE shares as ‘Outperform’, setting a target price of $27 on the company’s shares in an initiating report dated March 18, 2025. Wedbush Initiated an Outperform rating on September 04, 2024, and assigned a price target of $45. Evercore ISI initiated its ‘Outperform’ rating for SYRE, as published in its report on July 16, 2024. Robert W. Baird’s report from May 02, 2024 suggests a price prediction of $50 for SYRE shares, giving the stock a ‘Outperform’ rating. Wells Fargo also rated the stock as ‘Overweight’.
Analysis of Spyre Therapeutics Inc (SYRE)
Spyre Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -41.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.49, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and SYRE has an average volume of 607.03K. On a monthly basis, the volatility of the stock is set at 7.55%, whereas on a weekly basis, it is put at 13.92%, with a gain of 31.09% over the past seven days. Furthermore, long-term investors anticipate a median target price of $52.91, showing growth from the present price of $21.0, which can serve as yet another indication of whether SYRE is worth investing in or should be passed over.
How Do You Analyze Spyre Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.51%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 99.42% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
